BofA Securities initiated coverage of Beta Bionics with a rating of Buy
Get the next $BBNX alert in real time by email
Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $BBNX
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/24/2025 | Buy | BofA Securities | |
| 2/24/2025 | $30.00 | Buy | Lake Street |
| 2/24/2025 | $25.00 | Buy | Stifel |
| 2/24/2025 | $26.00 | Overweight | Piper Sandler |
| 2/24/2025 | $28.00 | Outperform | Leerink Partners |
| 2/20/2025 | $20.00 | Neutral | Ladenburg Thalmann |
| 2/20/2025 | $20.00 | Neutral | Robert W. Baird |
Beta Bionics to Announce Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025
IRVINE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its fourth quarter and full year 2024 financial results after the financial markets close on Tuesday, March 25, 2025. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company's fourth quarter and full year 2024 performance. The link to the webcast will be available on the Company's website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archived
Beta Bionics Announces Closing of $234.6 Million Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
IRVINE, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the closing of its upsized initial public offering of 13,800,000 shares of common stock, including the full exercise of the underwriters' option to purchase 1,800,000 additional shares, consisting of 475,000 additional shares from Beta Bionics and 1,325,000 shares from the selling stockholders named in the prospectus, at a price to the public of $17.00 per share. The gross proceeds to Beta Bionics from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by B
BofA Securities initiated coverage on Beta Bionics
BofA Securities initiated coverage of Beta Bionics with a rating of Buy
Lake Street initiated coverage on Beta Bionics with a new price target
Lake Street initiated coverage of Beta Bionics with a rating of Buy and set a new price target of $30.00
Stifel initiated coverage on Beta Bionics with a new price target
Stifel initiated coverage of Beta Bionics with a rating of Buy and set a new price target of $25.00
Chief Product Officer Mensinger Mike bought $566,950 worth of shares (33,350 units at $17.00), converted options into 15,107 shares, exercised 10,575 in-the-money shares at a strike of $0.02 and sold $221 worth of shares (13 units at $17.00) (SEC Form 4)
4 - Beta Bionics, Inc. (0001674632) (Issuer)
Large owner Wellington Hadley Harbor Aggregator Iv, L.P. converted options into 2,901,599 shares and bought $17,000,000 worth of shares (1,000,000 units at $17.00) (SEC Form 4)
4 - Beta Bionics, Inc. (0001674632) (Issuer)
Chief Financial Officer Feider Stephen was granted 47,000 shares (SEC Form 4)
4 - Beta Bionics, Inc. (0001674632) (Issuer)
Chief Commercial Officer Hopman Mark was granted 35,000 shares (SEC Form 4)
4 - Beta Bionics, Inc. (0001674632) (Issuer)
President & CEO Saint Sean was granted 108,000 shares (SEC Form 4)
4 - Beta Bionics, Inc. (0001674632) (Issuer)
SEC Form SCHEDULE 13G filed by Beta Bionics Inc.
SCHEDULE 13G - Beta Bionics, Inc. (0001674632) (Subject)
SEC Form SCHEDULE 13G filed by Beta Bionics Inc.
SCHEDULE 13G - Beta Bionics, Inc. (0001674632) (Subject)
SEC Form S-8 filed by Beta Bionics Inc.
S-8 - Beta Bionics, Inc. (0001674632) (Filer)
Beta Bionics to Announce Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025
IRVINE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its fourth quarter and full year 2024 financial results after the financial markets close on Tuesday, March 25, 2025. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company's fourth quarter and full year 2024 performance. The link to the webcast will be available on the Company's website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archived